相似化合物
915226-43-6 4138-27-6 168749-30-2上下游产品
CAS号71381-75-4 1-B°C-哌啶-3-羧酸 | CAS号4138-26-5 3-哌啶甲酰胺 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号91419-53-3 1-B°C-3-氰基哌啶 | CAS号274682-80-3 3-氨基硫基氧代甲基-1-哌啶... | CAS号162167-97-7 1-B°C-3-氨甲基哌啶 | CAS号91419-64-6 3-(1H-Tetrazol-...合成工艺路线路线简述
- 24424-99-5 + 4138-26-5 = 91419-49-7
反应条件:1.1 Catalysts: 4-(Dimethylamino)Pyridine Solvents: Acetonitrile; 24 H,Rt
标题:Design,Synthesis And Preliminary Pharmacological Evaluation Of New Piperidine And Piperazine Derivatives As Cognition-Enhancers
作者:Martini,Elisabetta; Et Al
参考文献:Bioorganic & Medicinal Chemistry 日期:2008 卷标:16(3) 页码:1431-1443
📜1-Boc-哌啶-3-羧酸置于吡啶,二碳酸二叔丁酯,碳酸氢铵体系中,用 1,4-二氧六环 作为反应溶剂,化学反应 20.0H,反应生成 1-Boc-3-氨基甲酰基哌啶
参考文献:Dihydroxypyrimidine-4-Carboxamides作为新型有效和选择性的hiv整合酶抑制剂.
标题:Dihydroxypyrimidine-4-Carboxamides作为新型有效和选择性的hiv整合酶抑制剂.
摘要:人类免疫缺陷病毒1型(hiv-1)整合酶是复制所需的三种组成型病毒酶之一,是化学疗法干预aids的合理靶标,最近在临床环境中也得到了证实.我们在这里报告的n-苄基5,6-二羟基嘧啶-4-羧酰胺的设计和合成作为一类药物,对hiv整合酶催化的链转移过程具有有效的抑制作用.在当前的研究中,对这些分子进行了结构修饰,以检查其对hiv整合酶抑制效能的影响.该系列中最有趣的化合物之一是2-[1-(二甲基氨基)-1-甲基乙基]-N-(4-氟苄基)-5,6-二羟基嘧啶-4-羧酰胺38,Cic95为78 Nm.在血清蛋白存在下进行基于细胞的测定.
DOI:10.1021/jm070027U
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2912110000-甲醛
2912120000-乙醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2008194629-A1
优先权日:2005-05-03
标题 :3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors
发明人:BAESCHLIN DANIEL KASPAR; BREITENSTEIN WERNER; EHRHARDT CLAUS; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; ZIMMERMANN JUERG; RUDISSER SIMON; VANGREVELINGHE ERIC; IRIE OSAMU; UMEMURA ICHIRO; SUZUKI MASAKI; MOGI MUNETO; KANAZAWA TAKANORI; YOKOKAWA FUMIAKI; NIHONYANAGI ATSUKO
权利人:BAESCHLIN DANIEL KASPAR; BREITENSTEIN WERNER; EHRHARDT CLAUS; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; ZIMMERMANN JUERG; RUDISSER SIMON; VANGREVELINGHE ERIC; IRIE OSAMU; UMEMURA ICHIRO; SUZUKI MASAKI; MOGI MUNETO; KANAZAWA TAKANORI; YOKOKAWA FUMIAKI; NIHONYANAGI ATSUKO
摘要:The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.